Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment

Fukuda, Hiroyuki; Numata, Kazushi; Hara, Koji; Nozaki, Akito; Kondo, Masaaki; Chuma, Makoto; Nakano, Masayuki; Nozawa, Akio; Maeda, Shin; Tanaka, Katsuaki

doi:10.7150/jca.24236

Cited by 8 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the therapeutic evaluation of sorafenib for HCC using CEUS has been reported, there are only a few reports on LEN. 10 , 11 , 12 , 13 We hypothesized that blood flow evaluation by CEUS is useful in predicting the therapeutic effect of LEN. In this study, we investigated whether the therapeutic effect of LEN could be accurately assessed using the minimally invasive measurement of blood flow in HCC during the early stages of treatment.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound

et al. 2021

View full text Add to dashboard Cite

Background: The antitumor effect of a drug is considered to be associated with a decrease in tumor blood flow.Aims: We investigated whether the efficacy of lenvatinib (LEN) could be accurately assessed by measuring blood flow in hepatocellular carcinoma (HCC) during early treatment stages.Methods and results: Blood flow changes and treatment results of 19 patients who underwent contrast-enhanced ultrasound (CEUS), before and after LEN administration, in Kurume University Hospital from July 2018 to June 2020 were examined.Blood flow was evaluated after the intravenous administration of perflubutane (0.015 ml/kg). The vascular phase was photographed and used as RAW data, and timeintensity curve analysis was used to obtain the region of interest (ROI) on the entire tumor nodule and quantify tumor blood flow. The evaluation was performed before and 1 and 4 weeks after LEN administration. Mean ± standard deviation (SD) values of the brightness of blood flow in the background liver before and 1 and 4 weeks after LEN administration were 2.84 Â 10 À4 ± 2.94 Â 10 À4 , 3.07 Â 10 À4 ± 3.79 Â 10 À4 , and 10.0 Â 10 À4 ± 20.8 Â 10 À4 dB, respectively. Blood flow in the background liver did not significantly decrease at 1 and 4 weeks compared with that before treatment. Mean ± SD values of the brightness of blood flow in HCC before and 1 and 4 weeks after administration were 3.49 Â 10 À3 ± 4.58 Â 10 À3 , 1.16 Â 10 À3 ± 1.57 Â 10 À3 , and 6.39 Â 10 À3 ± 22.8 Â 10 À3 dB, respectively. Blood flow in HCC after 1 week was significantly lower than that before administration (p = .0192). The therapeutic effects were significantly higher in the group with ≥50% blood flow reduction in HCC at 1 week after administration (p = .0038) and the group with reduced blood flow in HCC at 4 weeks after administration (p = .0051) than those before administration.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound

et al. 2021

View full text Add to dashboard Cite

show abstract

“…With the administration of an ultrasonographic contrast agent, CE-US brings a higher signal-to-noise ratio and a higher sensitivity for slow flow than traditional B-mode US (9). CE-US has been widely used in many fields including hepatocellular carcinomas (HCC), breast cancers, and colorectal cancers (10)(11)(12). Previous studies have evaluated the efficacy of chemotherapy in different cancers using CE-US, and reported that CE-US could be useful in evaluating tumor progression by detecting changes in tumor vascularity (10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

“…CE-US has been widely used in many fields including hepatocellular carcinomas (HCC), breast cancers, and colorectal cancers (10)(11)(12). Previous studies have evaluated the efficacy of chemotherapy in different cancers using CE-US, and reported that CE-US could be useful in evaluating tumor progression by detecting changes in tumor vascularity (10)(11)(12). Kudo et al compared B-mode US with CE-US for the surveillance of HCC and recommended CE-US as a useful detection method for HCC (13).…”

Section: Introductionmentioning

confidence: 99%

Comparison between B-mode ultrasonography and contrast-enhanced ultrasonography for the surveillance of early stage pancreatic cancer: a retrospective study

Zhang

Cheng

2020

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Contrast-enhanced ultrasonography (CE-US) brings a higher signal-to-noise ratio and a higher sensitivity for slow flow than traditional B-mode ultrasonography (US). However, it remains unclear whether CE-US is also superior to B-mode US in detecting early-stage pancreatic cancer (PC).Methods: This was a retrospective study enrolling patients suspected of pancreatic insufficiency between June 2015 and December 2019. Enrolled patients successively received B-mode US and CE-US examinations, and some their demographic and clinical data were collected. The diagnostic capacity of the two examinations was calculated and receiver operating characteristic (ROC) curves was used to compare the area under the curve (AUC). A subgroup analysis was performed to explore the effects of tumor size on the diagnostic accuracy of B-mode US and CE-US Results: There were 128 patients enrolled in this study; 74 patients were diagnosed as early-stage PC patients and the remaining 54 were diagnosed with benign pancreatic lesions. The mean size of the PC was 17.8±4.9 mm. The results revealed that 68 of the 74 PC patients were correctly diagnosed by CE-US, and all 54 patients with benign pancreatic lesions were also correctly diagnosed. Meanwhile, only 55 of the 74 PC patients and 50 of the 54 patients with benign pancreatic lesions were diagnosed correctly using B-mode US. The ROC curve showed that the AUCs of CE-US and B-mode US were 0.959 and 0.835, respectively.According to the subgroup analysis, CE-US exhibited better accuracy than B-mode US for smaller tumors

show abstract

“…Sorafenib inhibits the RAS/RAF/MEK/ERK signaling pathway by inhibiting the activity of RAF, thereby directly suppresses tumor cell proliferation, and induces apoptosis of cancer cells [16]. On the other hand, SOR can also inhibit neovascularization and cut off the supply of tumor nutrition, thereby inhibiting tumor growth and metastasis [17]. And SOR as a chemical drug has a broad-spectrum antitumor effects and is commonly used in the treatment of liver and kidney cancer.…”

Section: Introductionmentioning

confidence: 99%

Sorafenib‐Loaded Long‐Circulating Nanoliposomes for Liver Cancer Therapy

Zhou

Jin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

A type of sorafenib- (SOR-) loaded long-circulating nanoliposome was constructed, and the targeting performance and antitumor effects of the prepared liposome were evaluated in the present study. Polyethylene glycol- (PEG-) modified long-circulating nanoliposomes (LC-NPs) were designed and prepared using reverse evaporation, and the LC-NPs were used for delivering sorafenib (LC-PEG-SOR-NPs). Then, the anti-VEGFR antibody as a targeting moiety was chemically coupled with LC-PEG-SOR-NPs to form liver cancer-targeted nanoliposomes (anti-VEGFR-LC-PEG-SOR-NPs). The drug entrapment and loading efficiency were measured. And the cancer-targeting performance and therapeutic efficiency were evaluated both in vitro and in vivo. The anti-VEGFR-LC-PEG-SOR-NPs with an average of 119.8±4.2 nm showed a uniform spherical structure. The drug entrapment and loading efficiency were 92.5% and 18.5%, respectively. The killing efficiency of anti-VEGFR-LC-PEG-SOR-NPs was up to 18% after incubating with liver cancer cells for 72 h. Furthermore, the anti-VEGFR-LC-PEG-SOR-NPs could actively target at the tumor region and could efficiently inhibit tumor growth with negligible side effects. This newly designed nanoliposomes had desirable dispersibility, high drug entrapment efficiency, tumor targeting and therapeutic efficiency, and good safety. As a biocompatible nanocomposite, it was promising to become a novel and useful tumor-targeting nanodrug for liver cancer therapy.

show abstract

Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment

Cited by 8 publications

References 30 publications

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound

Comparison between B-mode ultrasonography and contrast-enhanced ultrasonography for the surveillance of early stage pancreatic cancer: a retrospective study

Sorafenib‐Loaded Long‐Circulating Nanoliposomes for Liver Cancer Therapy

Contact Info

Product

Resources

About